Multiple Myeloma Clinical Trial
Official title:
Pilot Study of Donor Th2 Cells for the Prevention of Graft-Versus-Host Disease in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Verified date | May 19, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Allogeneic peripheral blood stem cell transplantation (PBSCT) is primarily limited by
graft-versus-host disease (GVHD). In murine models, we have demonstrated that donor CD4+ T
cells of Th1 cytokine phenotype (defined by their secretion of IL-2 and IFN-gamma) mediate
GVHD. In contrast, donor CD4+ T cells of Th2 phenotype (defined by their secretion of IL-4,
IL-5, and IL-10) do not generate GVHD, and abrogate Th-1-mediated GVHD. Importantly, we have
demonstrated that enrichment of murine allografts with Th2 cells reduces GVHD without
impairing the ability of donor T cells to prevent graft rejection. These studies indicate
that the administration of Th2 cells after allogeneic transplantation represents a strategy
for achieving alloengraftment with reduced GVHD.
In addition to GVHD, allogeneic PBSCT has been limited by the toxicity associated with
conventional myeloablative preparative regimens. Such regimens, which typically utilize total
body irradiation (TBI) and high-dose chemotherapy, were once considered essential for the
prevention of graft rejection. However, recent clinical studies have shown that
non-myeloablative doses of fludarabine-based chemotherapy can result in alloengraftment. In
murine models, we have demonstrated that severe host T cell depletion induced by combination
fludarabine and cytoxan can prevent even fully-MHC mismatched marrow graft rejection.
Although non-myeloablative regimens may reduce regimen-related toxicity, such transplants
have been associated with a 30 to 40% incidence of severe acute GVHD that is similar to rates
observed with myeloablative regimens. Because non-myeloablative regimens appear to be
associated with reduced regimen-related toxicity, we have elected to conduct this phase I
study of Th2 cells in the setting of an immunoablative (non-myeloablative) preparative
regimen.
Patients with leukemia in clinical remission, and patients with refractory lymphoid
malignancy will be candidates for this HLA-matched allogeneic PBSCT protocol. Patients will
receive novel induction regimen (fludarabine and EPOCH) and transplant preparative regimen
(fludarabine and cytoxan) designed to maximally deplete host immune T cells capable of
mediating graft rejection. After induction and preparative regimen chemotherapy, patients
will receive an unmanipulated, G-CSF mobilized PBSC graft. In the initial six patients
receiving this transplant procedure at the NCI, graft rejection has been successfully
prevented (100% donor chimerism by day 30 post-transplant). Importantly, GVHD has been
observed in all six patients, with three of the six patients developing severe GVHD (grade
III). Given that this regimen successfully achieves donor engraftment, and is associated with
significant GVHD, this transplant regimen represents an excellent clinical setting for the
evaluation of Th2 cells.
Using this non-myeloablative allogeneic PBSCT approach, we will perform a Phase I study to
evaluate the safety and feasibility of administering donor Th2 cells on day 1
post-transplant. Prior to transplantation, donor CD4+ T cells will be stimulated in vitro
using culture conditions that support the generation of donor CD4 cells of the Th2 cytokine
profile. If this Phase I study demonstrates that Th2 cell administration is safe and
feasible, a Phase III study will be performed to evaluate whether Th2 cell administration
reduces the incidence and severity of GVHD. Successful implementation of this Th2 strategy
will greatly reduce the morbidity and mortality associated with allogeneic PBSCT, and may
also represent an approach to stem cell transplantation in patients lacking an HLA-matched
donor.
Status | Completed |
Enrollment | 110 |
Est. completion date | May 19, 2015 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 75 Years |
Eligibility |
- INCLUSION CRITERIA - Patient: Patients with lymphoid malignancy and leukemia (including myelodysplasia) are candidates for this study. The following diagnoses and ages will be considered: Chronic Lymphocytic Leukemia, Age 18-75 1. Relapse Post-fludarabine, or 2. Non-CR after Salvage Regimen Hodgkin's and Non-Hodgkin's Lymphoma (all types, including Mantle Cell Lymphoma), Age 18-75 1. Primary Treatment Failure, or 2. Relapse after AutoSCT, or 3. Non-CR after Salvage Regimen Multiple Myeloma, Age 18-75 1. Primary Treatment Failure, or 2. Relapse after AutoSCT, or 3. Non-CR after Salvage Regimen Acute Myelogenous Leukemia, Age 18-75 1. In CR #1, 2, or 3 2. Any Relapse with less than 10% blasts (marrow and blood) Acute Lymphocytic Leukemia, Age 18-75 1. In Complete Remission #2 2. In Complete Remission #3 3. Any Relapse with less than 10% blast (marrow and blood). Myelodysplastic Syndrome, Age 18-75 1. RAEB 2. RAEB-T (if blasts are less than 10% in marrow and blood after induction chemotherapy) Chronic Myelogenous Leukemia, Age 18-75 1. Chronic Phase CML 2. Accelerated Phase CML Patient age of at least 18 and not greater than 75 years of age. Availability of 6/6 antigen (A, B, and DR) HLA-matched sibling donor. Karnofsky performance status of greater than or equal to 70%. Life expectancy greater than 3 months. Serum bilirubin less than 2.5 mg/dL, and serum ALT and AST values less than or equal to 2.5 times the upper limit of normal. Values above these levels may be accepted, at the discretion of the PI or study chairman, if such elevations are thought to be due to tumor involvement by the lymphoid malignancy. If these values do not normalize during the induction chemotherapy, such patients will not be eligible for the transplant phase of the protocol, and will thus be taken off study. Creatinine clearance greater than or equal to 60 ml/min or serum creatinine of less than or equal to 1.5 mg/dl. DLCO greater than 50% of predicted. Left ventricular ejection fraction of greater than or equal to 45% by MUGA or ECHO. Ability to give informed consent. Durable power of attorney form completed. INCLUSION CRITERIA - Donor: Must be sibling, matched with recipient at 6/6 of the HLA loci (A, B, and DR). Adequate venous access for peripheral apheresis, or consent to use a temporary central venous catheter for apheresis. Must be at least 12 years of age. Ability to give informed consent. For donors under 18 years of age, an assent form must be completed. EXCLUSION CRITERIA - Patient: Infection that is not responding to anti-microbial therapy. Active CNS involvement by tumor. HIV positive (due to unacceptable risk after allogeneic transplantation). Hepatitis B or C surface antigen positive. Lactating or pregnant females (due to risk to fetus or newborn). History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent (as determined by principal investigator or study chairman). EXCLUSION CRITERIA - Donor: History of psychiatric disorder which may compromise compliance with transplant protocol, or which does not allow for appropriate informed consent. History of hypertension that is not controlled by medication, stroke, or severe heart disease. Individuals with symptomatic angina, or a history of coronary artery bypass grafting or angioplasty will be considered to have severe heart disease, and thus will not be eligible to be a donor. Anemia (Hb less than 11 gm/dl) or thrombocytopenia (PLT less than 100,000 per ul). Lactating or pregnant females. HIV positive. Hepatitis B or C antigen positive. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol. 2000 Dec 1;18(23):3918-24. — View Citation
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S, Read EJ, Carter C, Bahceci E, Young NS, Barrett AJ. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999 Nov 1;94(9):3234-41. — View Citation
Wäsch R, Bertz H, Kunzmann R, Finke J. Incidence of mixed chimaerism and clinical outcome in 101 patients after myeloablative conditioning regimens and allogeneic stem cell transplantation. Br J Haematol. 2000 Jun;109(4):743-50. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |